Regulatory

Change in number of shares and votes in Ascelia Pharma AB (publ)

2019-03-29
Download

During March, the registered number of shares and votes in Ascelia Pharma AB (publ) has increased due to the new issue that was executed in connection with the listing of the company’s shares on Nasdaq Stockholm. As of 29 March 2019, the registered number of shares and votes in Ascelia Pharma AB (publ) amounts to 22,606,891.

For more information, please contact
Magnus Corfitzen, CEO
Email:
moc@ascelia.com
Tel: +46 735 179 110

Mikael Widell, IR & Communications Manager
Email:
mw@ascelia.com
Tel: +46 703 11 99 60

This information is such information as Ascelia Pharma AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 5.15 p.m. CET on 29 March 2019.


About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com 

2020-09-18

First commercial scale manufacturing of Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the company has reached a key achievement with the first commercial scale manufacturing of its lead compound Mangoral, currently in pivotal Phase 3 development. The commercial scale manufacturing is an important step towards market launch.
2020-08-20

Quarterly Report Q2-2020: First participant in the hepatic study

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2-2020 (April – June 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/
2020-07-31

Change in number of shares and votes in Ascelia Pharma AB